posted
***PKTX..We Have PR News.. :+O ProtoKinetix AAGP® Molecule Moving Forward in Key Healthcare Studies Targeting Important Health Care SolutionsPress Release | 09/04/2018
ProtoKinetix, Incorporated (www.protokinetix.com) (the "Company" or "ProtoKinetix") (OTCQB:PKTX)
...President and Chief Executive Officer Clarence Smith is pleased at the progress of the health care applications projects the Company has underway. According to Mr. Smith “To that end, ProtoKinetix is continuing to collaborate with some of the most prestigious research institutions.
..The Company is focusing on research efforts in areas where our AAGP® molecule can significantly impact the success of healthcare outcomes.” ***I invite you to click on the links below for more detailed information.
***The company plans to introduce video content to its website that will allow for more detailed updates.
Current projects underway include the following:
1. Solutions for Diabetes Diabetes study currently in a Phase 1 human trial. Clinicaltrials.gov - Islet Transplantation Using PKX-001.
a) Cryopreservation of primary mammalian tissue cells b) Enhancing the viability of primary mammalian cells c) Cell lines under stressed culture conditions
a) Immune Cell Cryopreservation recovery, ‘study completed’
In Our Current Pipeline:
Two studies with an undetermined start dates are Kidney Ischemia and Liver Perfusion. The company is actively negotiating material transfer agreements with other companies for collaborative research studies. CEO Clarence Smith notes that the company has adequate cash on hand for project continuation and company operations for the near term.
posted